Aroa Biosurgery Limited (ASX:ARX)

Australia flag Australia · Delayed Price · Currency is AUD
0.605
-0.015 (-2.42%)
Mar 9, 2026, 12:09 PM AEST
23.47%
Market Cap 214.20M
Revenue (ttm) 79.26M
Net Income (ttm) -1.60M
Shares Out 345.48M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE 46.70
Dividend n/a
Ex-Dividend Date n/a
Volume 41,902
Average Volume 155,992
Open 0.610
Previous Close 0.620
Day's Range 0.600 - 0.615
52-Week Range 0.350 - 0.800
Beta 0.80
RSI 39.61
Earnings Date May 31, 2026

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2007
Country New Zealand
Stock Exchange Australian Securities Exchange
Ticker Symbol ARX
Full Company Profile

Financial Performance

In fiscal year 2025, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2024.

Financial numbers in NZD Financial Statements

News

There is no news available yet.